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Effect of nitric oxide modulation on TGF-b1 and matrix pro- icity [1, 2]. Chronic CsA nephrotoxicity may progress
teins in chronic cyclosporine nephrotoxicity. to an irreversible renal lesion characterized by striped
Background. Chronic cyclosporine (CsA) nephrotoxicity is tubulointerstitial fibrosis and hyalinosis of the afferentcharacterized by interstitial fibrosis and afferent arteriolar hya-
arterioles [3]. While acute CsA nephrotoxicity is thoughtlinosis. l-arginine (L-Arg), the substrate for nitric oxide (NO)
to result from intrarenal vasoconstriction, the mecha-synthase and N-nitro-l-arginine-methyl ester (L-NAME), the
NO synthase inhibitor, were shown to modulate acute CsA nism leading to the fibrosis of chronic CsA nephrotoxic-
nephrotoxicity. However, the mechanism of fibrosis in chronic ity remains unclear. In order to study chronic CsA neph-
CsA nephrotoxicity remains unclear. Thus, we examined the rotoxicity, a reproducible animal model with physiologiceffect of NO modulation on fibrosis and the expression of trans-
and histologic features in the kidney that resemble theforming growth factor-b1 (TGF-b1) and matrix proteins in
chronic CsA nephrotoxicity. human lesion described in patients on long-term CsA
Methods. Rats were administered CsA (7.5 mg/kg), CsA 1 therapy was developed [4]. Our previous studies using
L-Arg (1.7 g/kg), CsA 1 L-NAME (3.5 mg/kg), vehicle (VH), the same model have shown that transforming growth
VH 1 L-Arg, and VH 1 L-NAME, and were sacrificed at 7 or
factor-b1 (TGF-b1), a key fibrogenic cytokine implicated28 days. NO production, physiologic parameters, and histology
in the fibrosis of a number of chronic diseases, is involvedwere studied in addition to the mRNA expression of TGF-b1,
plasminogen activator inhibitor-1 (PAI-1) and the matrix pro- in the fibrosis of chronic CsA nephrotoxicity by increasing
teins biglycan and collagens type I and IV by Northern and matrix protein synthesis and by decreasing matrix degra-
the protein expression of PAI-1 and fibronectin by enzyme- dation through increasing the activity of plasminogenlinked immunosorbent assay.
activator inhibitor-1 (PAI-1) [5, 6]. We have also shownResults. While L-NAME strikingly reduced NO biosynthesis
that the renin-angiotensin system (RAS) is up-regulatedand worsened the glomerular filtration rate and CsA-induced
fibrosis, L-Arg had the opposite beneficial effect. In addition, in this model and that blocking the RAS was beneficial
the CsA-induced up-regulated expression of TGF-b1, PAI-1, in reducing fibrosis and the expression of TGF-b1 and
and the matrix proteins biglycan, fibronectin, and collagen I was
various matrix components [7].significantly increased with L-NAME and strikingly improved
In the kidney, nitric oxide (NO) is a vasoactive factorwith L-Arg. Collagen IV expression was not affected. Also,
NO modulation did not affect VH-treated rats. important in maintaining vascular tone [8]. NO is pro-
Conclusions. Chronic CsA nephrotoxicity can be aggravated duced from l-arginine (L-Arg) by the action of NO syn-
by NO blockade and ameliorated by NO enhancement, sug- thase (NOS) isoforms. The three NOS isoforms are pres-gesting that NO maintains a protective function. NO modula-
ent in the kidney [9]. Neuronal NOS (NOS-I) exhibitstion was associated with a change in TGF-b1 expression, which,
a macula densa cell specific expression. Inducible NOSin turn, was associated with alterations in matrix deposition
and matrix degradation through its effect on PAI-1. (NOS-II) was observed in mesangial and proximal tubular
cells, and endothelial NOS (NOS-III) is expressed mainly
in endothelial cells of afferent and efferent arterioles
The major dose-limiting adverse effect of long-term and in glomerular capillaries. While NOS-I and NOS-III
cyclosporine (CsA) administration is chronic nephrotox- are constitutively expressed, NOS-II is normally unde-
tectable in the kidney and is induced by cytokines [10].
Dietary L-Arg supplementation was shown to have ben-Key words: collagen, extracellular matrix, fibrosis, glycoprotein, l-argi-
nine, plasminogen activator inhibitor-1, afferent arteriolar hyalinosis. eficial effects in a number of experimental renal diseases
presumably because it increases NO production [11–14].Received for publication January 24, 2000
In contrast, N-nitro-l-arginine-methyl ester (L-NAME),and in revised form April 4, 2000
Accepted for publication April 14, 2000 a potent competitive inhibitor of NO synthesis, was
shown to worsen kidney disease. In the kidney, NO is notÓ 2000 by the International Society of Nephrology
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only involved in glomerular hemodynamics regulation, L-Arg and continued for 7 or 28 days. Four additional
groups received L-NAME (Sigma Chemical Co.) andwater-electrolyte balance, and renin production but was
also shown to prevent glomerular thrombosis and ische- were treated with VH (two groups) or CsA (two groups)
at 7.5 mg/kg/day for 7 or 28 days. L-NAME was dissolvedmia [14, 15], lessen mesangial cell proliferation, decrease
extracellular matrix protein synthesis [16], and decrease in distilled water at a concentration of 5 mg/100 mL. The
rats were allowed free access to L-NAME solution ininterstitial macrophage infiltration [17].
Several in vivo and in vitro studies have suggested standard drinking bottles. The average daily intake for
the rats was 23 mL (3.5 mg of L-NAME per kg). Thethat alterations of the NO pathway may be involved in
the renal vasoactive responses and functional impairment doses were chosen based on previous experiments done
in the same model [25, 26].seen with experimental acute CsA administration [18–24].
NO causes a relaxation of preglomerular arteries, thus The experimental groups of rats were categorized as
follows: group 1, CsA (7 days); group 2, CsA 1 L-NAMEimproving renal blood flow. The endothelial-dependent
vasodilation mediated by NO is impaired during acute (7 days); group 3, CsA 1 L-Arg (7 days); group 4, VH
(7 days); group 5, VH 1 L-NAME (7 days), group 6,CsA treatment and can be enhanced by simultaneous
NOS inhibition with L-NAME, resulting in reductions VH 1 L-Arg (7 days); group 7, CsA (28 days); group 8,
CsA 1 L-NAME (28 days); group 9, CsA 1 L-Arg (28in the glomerular filtration rate (GFR) [25]. Recently,
dietary L-Arg supplementation was shown to be protec- days); group 10, VH (28 days); group 11, VH 1 L-NAME
(28 days); and group 12, VH 1 L-Arg (28 days).tive in chronic CsA nephrotoxicity [26]. However, only
the histologic and physiologic changes were assessed, After each treatment period, systolic blood pressure
was measured by tail plethysmography (Natsume Seisa-and the mechanism leading to this beneficial effect was
not studied. kusyo, Tokyo, Japan), and 24-hour urine samples were
collected in metabolic cages (Nalge, Rochester, NY, USA)Thus, we tested the hypothesis that if CsA administra-
tion alters intrarenal NO synthesis, then potentially into a plastic tube cooled with ice. The following day,
rats were anesthetized with intraperitoneal ketamine.chronic NO blockade could worsen and chronic exoge-
nous L-Arg administration could limit renal dysfunction The abdomen was opened through a midline incision,
and the aorta was cannulated retrogradely below theand, more importantly, could have a beneficial effect on
the fibrosis and the expression of TGF-b1 and extracellu- renal arteries with an 18-gauge needle. With the aorta
occluded by ligation above the renal arteries and thelar matrix proteins in the setting of chronic CsA nephro-
toxicity. Conditions of chronic NO blockade were estab- renal veins opened by a small incision for outflow, the
kidneys were perfused with 20 mL of cold heparinizedlished with L-NAME and chronic NO enhancement with
L-Arg supplementation. Our study results support the saline. The left kidney was removed and processed for
light microscopy and protein analysis. After removinghypothesis that NO maintains a protective function in
chronic CsA nephrotoxicity. the right kidney, the cortex was dissected from the me-
dulla, and the whole cortex was processed for RNA
analysis. After the experiment, the animals were euthan-
METHODS
ized by deep anesthesia with ketamine followed by ex-
Experimental design sanguination because of transection of a major blood
vessel.Adult male Sprague-Dawley rats (Charles River, Wil-
mington, MA, USA) weighing 200 to 250 g at the beginning
Functional studiesof the study were used. They were housed in individual
cages in a temperature- and light-controlled environ- Blood was collected from the jugular vein in plastic
syringes transferred to metal-free tubes and chilled onment and received a low-salt diet (0.05% sodium; Teklad
Premier, WI, USA), with water ad libitum. Animals were ice. Plasma was harvested immediately by centrifugation
at 48C and stored at 2708C until determined. Urinarypair fed and were weighed and examined daily. After 7
or 28 days on the low-salt diet, weight-matched pairs of and plasma creatinine were measured by a Cobas auto-
analyzer (Roche Diagnostics, Div. Hoffman-La Rocherats were randomized into six groups of six animals for
a total of 12 experimental groups. Four groups were Inc., Nutley, NJ, USA). Creatinine clearance (CCr) was
calculated using a standard formula. CsA blood levelstarted on L-Arg (Sigma Chemical, St. Louis, MO, USA)
at a dose of 1.7 g/kg/day added in powder form to a low- was measured by a monoclonal radioimmunoassay for
CsA (Incstar Co., Stillwater, MN, USA). Urinary excre-salt diet. After five days of L-Arg supplementation, CsA
(Sandoz Research Institute, East Hanover, NJ, USA) at tion of the stable NO metabolites NO2 and NO3 was
determined. Urinary NO2 was assayed by the Griess re-a dose of 7.5 mg/kg/d was administered subcutaneously
to two groups, while two separate groups received a agent [27]. Urinary NO3 was estimated by reduction to
NO2 using nitrate reductase from Aspergillus speciesweight-based identical volume of vehicle (VH) olive oil
as control. The CsA or VH was given concurrently with (Boehringer Mannheim Biochemicals, Indianapolis, IN,
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USA). The NO3 reduction was 95 to 100% effective. citrate (SSC), and 200 mg/mL denatured salmon sperm
DNA. They were then hybridized at 428C for 18 hoursUrinary NO3 excretion was considered the difference
between total NO2 (after reduction) minus initial NO2 with cDNA probes labeled with 32P-dCTP by random
oligonucleotide priming (Boehringer Mannheim). Thevalues. The results are expressed in mmol per 24 hours
of urine. blots were washed in 2 3 SSC, 0.1% SDS at room tem-
perature for 15 minutes and in 0.1 3 SSC, 0.1% SDS at
Morphology 508C for 15 minutes. Films were exposed at 2708C for
different time periods to ensure linearity of densitometricTissue samples were fixed in 10% buffered formalin
and were embedded in paraffin. Sections 2 to 4 m thick values and exposure time. Autoradiographs were scanned
on an imaging densitometer (GS-700; Bio-Rad Labora-were stained with periodic acid-Schiff’s reagent and tri-
chrome stain. Histologic findings were subdivided into tories, Hercules, CA, USA). The density of bands for the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)interstitial scarring and arteriolopathy. Tubulointerstitial
fibrosis consisted of matrix expansion with tubular dis- mRNA was used to control for differences in the total
amount of RNA loaded onto each gel line. For quantita-tortion and collapse and basement membranes thick-
ening. Features of interstitial inflammation included tive purposes, values were divided by the density of
bands for GAPDH in the same lane.mononuclear infiltrates, edema, and interstitial cells vac-
uolization. Renal arteriolopathy was characterized by The cDNA probes were a mouse TGF-b1 cDNA
probe (plasmid MUI5) kindly provided by R. Derynckeosinophilic granular transformation of afferent arteri-
oles and progressed to hyalinization and destruction of [28], a rat PAI-1 cDNA probe [plasmid pBluescript
SK(2)] obtained from T.D. Gelehrter [29], a humanthe afferent arterioles and terminal portions of interlobu-
lar arteries. A minimum of 20 fields at 3100 magnifica- biglycan cDNA probe (plasmid P16) from L.W. Fisher
[30], a rat procollagen a1 cDNA (plasmid pa1R1) ob-tion were assessed and graded in each biopsy by an
observer masked to treatment groups using a color image tained from D. Rowe [31], a rat collagen IV cDNA probe
(plasmid pCIV-1-PE16) purchased from American Typeanalyzer (Mustek Pentagon 800 SP, MacIntosh Power
PC 7100, NIH Image vs. 1.5). Culture Collection (Rockville, MD, USA) [32], and a
rat GAPDH cDNA probe (plasmid pBluescript KS II),Tubulointerstitial fibrosis was estimated by counting
the percentage of injured areas per field of cortex and a gift from J.M. Blanchard [33].
medulla and scored semiquantitatively as: 0 5 normal
Immunoassayinterstitium, 0.5 5 ,5% of areas injured, 1 5 5 to 15%,
1.5 5 16 to 25%, 2 5 26 to 35%, 2.5 5 36 to 45%, and Frozen (2708C) kidney tissue sections embedded in
Tissue-Tek O.C.T. compound (Miles Inc., Diagnostics3 5 .45%. Hyalinosis of the afferent arterioles was
semiquantitatively assessed by counting the percentage Div., Elkhart, IN, USA) were processed for protein ex-
traction. Tissue was thawed at 48C in 5 mL lysis bufferof juxtaglomerular afferent arterioles available for exam-
ination with a minimum of 100 glomeruli per biopsy (GITC/BME) and then rinsed in 5 mL cold 48C phos-
phate-buffered saline (PBS), pH 7.4. Protein extractsassessed: 0 5 no arterioles injured, 0.5 5 ,15%, 1 5 15
to 30%, 1.5 5 31 to 45%, 2 5 46 to 60%, 2.5 5 61 to were prepared by homogenizing kidney tissue in 1 mL
cold PBS containing 0.05% Tween 20 (PBS-T) with a75%, and 3 5 .75%.
glass tissue homogenizer (Kontes Glass, Vineland, NJ,
Northern blot analysis USA). The homogenate was centrifuged at 48C for 15
minutes at 15,000 3 g, and the supernatant was collectedRenal tissue was finely minced with a razor blade on
ice then homogenized in TRIzol reagent (GIBCO BRL, and then centrifuged to remove cellular debris. Protein
concentration in the supernatant was determined usingGrand Island, NY, USA). RNA extraction was performed
according to the manufacturer’s protocol. After resus- the Micro BCA (bicinchoninic acid) assay (Pierce, Rock-
ford, IL, USA).pension in Tris-ethylenediaminetetraacetic acid (EDTA)
buffer, RNA concentrations were determined using spec- To determine PAI-1 and fibronectin, an inhibitory en-
zyme-linked immunosorbent assay (ELISA) techniquetrophotometric readings at Absorbance260. Thirty micro-
grams of RNA were electrophoresed in each lane in 0.9% modified from the method of Rennard et al was used
[34]. Wells in a microtiter plate were coated with ratagarose gels containing 2.2 mol/L formaldehyde and 0.2
mol/L Mops (pH 7.0) and were transferred to a nylon PAI-1 antiserum (American Diagnostics, Greenwich,
CT, USA) or goat antirabbit fibronectin (Pierce). Tomembrane (ICN Biomedicals, Costa Mesa, CA, USA)
overnight by capillary blotting. Nucleic acids were cross- another plate, serial dilutions of standard or unknown
samples and rabbit IgG anti-PAI-1 (American Diagnos-linked by ultraviolet irradiation (Stratagene, La Jolla, CA,
USA). The membranes were prehybridized for two hours tics) or antifibronectin (American Diagnostics) were
added. After washing the coated plate, aliquots of theat 428C with 50% formamide, 10% Denhardt’s solution,
0.1% sodium dodecyl sulfate (SDS), 5 3 standard saline second plate were added to the coated plate and in-
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Table 1. Changes in creatinine clearance, urinary nitric oxide (NO) excretion, systolic blood pressure, and cyclosporine A (CsA) whole
blood level in the experimental groups at 7 and 28 days
Creatinine clearance Urinary NO Blood pressure CsA level
mL/min/100 g lmol/24 h mm Hg ng/mL
7 Days
CsA 0.3360.03 7.861.0 13064 12796207
CsA 1 L-NAME 0.27 60.02a 5.060.7a 13663 1331665
CsA 1 L-Arg 0.3560.01 12.261.4a,b 13265 13486124
VH 0.4260.01 7.961.0 12164 0
VH 1 L-NAME 0.37 60.02 5.361.0 13763 0
VH 1 L-Arg 0.4660.03 12.961.2a 13864 0
28 Days
CsA 0.2660.02a 6.961.2 12566 24226214
CsA 1 L-NAME 0.16 60.00a,b 4.160.7a,b 124633 19236498
CsA 1 L-Arg 0.3860.06a,b 13.662.3a,b 12762 2014656
VH 0.4160.02 8.561.2 12965 0
VH 1 L-NAME 0.43 60.02 5.460.9a 13967 0
VH 1 L-Arg 0.4460.04 13.161.9a 13362 0
Data are mean 6 SEM of six animals.
Abbreviations are: CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl ester; L-Arg, l-arginine; VH, placebo.
aP , 0.05 vs. VH
bP , 0.05 vs. CsA
Table 2. Semiquantitative scoring of tubulointerstitial fibrosis andcubated. After washing, horseradish peroxidase-conju-
arteriolopathy in the different groups at 7 and 28 days
gated goat antirabbit IgG (Pierce) was added and devel-
Tubulointerstitial fibrosis Arteriolopathyoped using standard methods. Absorbance (450 nm) was
7 Days 28 Days 7 Days 28 Daysread using a microtiter plate reader (Molecular Devices,
Palo Alto, CA, USA). CsA 0.160.1 2.160.3a 0.160.1 1.560.7a
CsA 1 L-NAME 0.2 60.1 2.860.3a 0.360.2 1.860.6a
CsA 1 L-Arg 0.060.0 0.960.2b 0.160.1 1.060.2bStatistical analysis
VH 0.060.0 0.160.1 0.060.0 0.160.1
Results are presented as mean 6 SE. Comparisons VH 1 L-NAME 0.0 60.0 0.160.1 0.060.0 0.160.1
VH 1 L-Arg 0.060.0 0.160.1 0.060.0 0.160.1between groups were done by analysis of variance
Data are mean 6 SEM of six animals.(Kruskal–Wallis test, followed by Tukey test). The level
Abbreviations are: CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methylof statistical significance was chosen as P , 0.05. ester; L-Arg, l-arginine; VH, placebo.
aP , 0.05 vs. VH
bP , 0.05 vs. CsA
RESULTS
Physiologic studies
Values for GFR, urinary excretion of NO, systolic blood nary NO excretion by 36 to 41% and 33 to 36% in the
CsA and VH groups, respectively. On the other hand,pressure, and CsA whole blood trough levels are summa-
rized in Table 1. Weight gain was progressive in all of urinary excretion of NO was significantly increased with
L-Arg treatment by 56 to 97% and 54 to 63%, respec-the treatment groups (data not shown). There were no
significant differences in body weight except in the CsA 1 tively, in the CsA and VH groups. While CsA treatment
lowered urinary NO excretion compared with the VHL-NAME group at 28 days, which failed to gain as much
weight (312 6 42 g, P , 0.05 vs. CsA, 393 6 7 g). Whole group, the difference did not achieve statistical signifi-
cance. There were no significant differences in systolicblood trough CsA levels progressively increased but re-
mained comparable among the CsA-treated groups. As blood pressure among all of the treatment groups. L-Arg
treatment did not lower the blood pressure in either theexpected, CsA treatment significantly decreased GFR
compared with the VH groups. L-NAME administration CsA or the VH groups.
significantly worsened GFR in the CsA-treated group,
Histologic changeswith the difference achieving statistical significance (P ,
0.05) at 28 days. On the other hand, L-Arg treatment The histologic changes observed are summarized in
Table 2. The VH rats treated with L-Arg or L-NAMEprotected animals treated with CsA from impaired GFR
but did not return the values to the VH-treated groups demonstrated normal kidney histology (Fig. 1A). By
contrast, the kidneys of the CsA groups had characteris-level. This effect was seen only in the CsA-treated groups
since NO manipulation with L-NAME and L-Arg did tic morphologic changes mostly evident at 28 days. CsA-
treated rats developed a striped pattern of tubulointersti-not change GFR in the VH-treated groups.
L-NAME administration significantly decreased uri- tial fibrosis and tubular atrophy (Fig. 1B). While L-NAME
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Fig. 1. Histologic changes in experimental chronic cyclosporine (CsA) nephrotoxicity. Photomicrographs showing the renal cortex of a salt-
depleted rat given olive oil (VH, vehicle; A), CsA at 7.5 mg/kg/day (B), a combination of CsA at 7.5 mg/kg/day and l-arginine (L-Arg) at 1.7
g/kg/day (C), or a combination of CsA at 7.5 mg/kg/day and N-nitro-l-arginine-methyl ester (L-NAME) at 3.5 mg/kg/day (D) for 28 days. In rats
treated with only CsA, interstitial fibrosis and tubular atrophy are seen relative to a medullary ray. When both CsA and L-Arg are given in
combination, the interstitial fibrosis and tubular atrophy are less severe. In contrast, when both CsA and L-NAME are given in combination, the
interstitial fibrosis and tubular atrophy are much more extensive (trichrome, magnification 3100).
treatment worsened the tubulointerstitial changes (Fig. and significantly more so at 28 days (P , 0.001) when
compared with the VH group (Figs. 2 and 3). L-NAME1D) at 28 days in the CsA group, L-Arg treatment re-
sulted in significantly (P , 0.05) less severe tubulointer- or L-Arg treatment in the VH groups had no effect on
TGF-b1 mRNA expression. In the CsA group, treatmentstitial fibrosis and tubular atrophy (Fig. 1C) compared
with the CsA-only treated group. The kidneys of CsA- with L-NAME was associated with an increased TGF-b1
expression that was observed as early as 7 days (P ,treated rats also showed prominent vascular lesions char-
acterized by hypertrophied smooth muscle cells of the 0.01), but became more significant (P , 0.001) at 28 days
compared with the VH group. In contrast, treatment ofafferent arterioles with characteristic granular eosino-
philic transformation. These arteriolar abnormalities were the CsA group with L-Arg reduced TGF-b1 expression
at seven days down to the VH group level (P , 0.001substantially worsened in animals treated with L-NAME,
although the changes did not attain statistical signifi- vs. CsA group). At 28 days, TGF-b1 expression was
reduced by 33% in the CsA 1 L-Arg group comparedcance. On the other hand, L-Arg treatment significantly
improved (P , 0.05) the CsA-induced arteriolopathy. with the CsA group (P , 0.001 vs. CsA), although L-Arg
treatment was not capable of reducing TGF-b1 expres-In addition, L-Arg treatment did not improve the tubulo-
interstitial fibrosis and arteriolopathy to the level ob- sion down to the VH group level.
The expression of PAI-1, a protease inhibitor thatserved in the kidneys of VH-treated animals.
blocks matrix degradation and is directly stimulated by
Expression of TGF-b1 and PAI-1 TGF-b, is shown in Figures 2 and 4. The expression of
PAI-1 paralleled that of TGF-b1, and the changes wereTransforming growth factor-b1 mRNA was progres-
sively increased in the CsA group by 7 days (P , 0.05) similar for both the mRNA expression by Northern and
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Fig. 3. Northern blot expression of transforming growth factor-b1
(TGF-b1) mRNA in rat kidneys relative to GAPDH. Total RNA was
Fig. 2. Northern blots of mRNA from the cortex of salt-depleted rat isolated from whole cortex at 7 and 28 days and was hybridized with a
kidneys. Representative gel of total RNA isolated from whole cortex cDNA probe to TGF-b1. Abbreviations are as follows: CsA, cyclosporine;
at 28 days from rats treated with CsA (7.5 mg/kg/day), CsA 1 L-NAME L-NAME, N-nitro-l-arginine-methyl ester; L-Arg, l-arginine; VH, pla-
(3.5 mg/kg/day), CsA 1 L-Arg (1.7 g/kg/day), VH, VH 1 L-NAME, and cebo. N 5 6 per group. *P , 0.05 vs. VH; #P , 0.05 vs. CsA.
VH 1 L-Arg. RNA was hybridized with cDNA probes to TGF-b1,
PAI-1, biglycan, type I collagen, type IV collagen, and GAPDH. Molec-
ular size markers are shown on the right. Abbreviations are as follows:
CsA, cyclosporine; L-NAME, N-nitro-l-arginine-methyl ester; L-Arg,
l-arginine; VH, placebo. groups for both 7 and 28 days. On the other hand, L-Arg
treatment significantly lowered the biglycan mRNA ex-
pression in the CsA group at 7 and 28 days to the levels
observed in the VH groups (P , 0.001).the protein expression by ELISA. Most of the changes
The protein expression of the glycoprotein fibronectinin the CsA groups were observed as early as 7 days (P ,
was studied by ELISA and is shown in Figure 6. CsA0.01), but were more dramatic at 28 days (P , 0.001)
treatment did not affect fibronectin expression until 28when compared with the VH groups. L-NAME treat-
days, when it became significantly higher than the VHment was associated with increased PAI-1 expression at
group (P , 0.01). The CsA 1 L-NAME group resulted7 and 28 days, and the changes were similar for both
in a markedly increased fibronectin expression that wasNorthern and ELISA. In sharp contrast, treatment with
seen at both 7 days (P , 0.01) and 28 days (P , 0.001).L-Arg was associated with a drop in PAI-1 mRNA and
Concomitant therapy with L-Arg in the CsA rats broughtprotein expressions to the levels observed in the VH-
the fibronectin levels down to that in the VH groups astreated groups for both 7 and 28 days.
early as 7 days and was persistent at 28 days. The expres-
Extracellular matrix deposition sion of fibronectin was similar in the VH, VH 1 L-NAME,
and VH 1 L-Arg groups.The proteoglycan biglycan is an extracellular matrix
Collagen type I is normally present in the interstitialcomponent that is directly stimulated by TGF-b; its
component of the kidney, and its expression is increasedmRNA expression is shown in Figures 2 and 5. The
in pathological conditions under TGF-b influence. Theexpression of biglycan was similar to TGF-b1 and was
mRNA expression of collagen type I is shown in Figuresprogressively elevated in the CsA-treated group com-
2 and 7A. In the CsA group, type I collagen mRNApared with the VH group at 7 days (P , 0.05) and
was similar to TGF-b1 and PAI-1 and was up-regulated28 days (P , 0.001), suggesting active matrix synthesis.
throughout the study period (P , 0.01) relative to theBiglycan mRNA expression was not affected by NO
VH group. Concomitant treatment with L-NAME re-modulation in the VH groups. Concomitant treatment
sulted in an increase in the expression of collagen typewith L-NAME in the CsA group resulted in a significant
I relative to the CsA group as early as 7 days (P , 0.05),increase in biglycan expression when compared with the
CsA only (P , 0.01) and the VH-treated (P , 0.01) although a more significant increase was seen at 28 days
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Fig. 4. Expression of PAI-1 in CsA and VH
treated rat kidneys. (A) Total RNA was iso-
lated from whole cortex at 7 and 28 days and
was hybridized with a cDNA probe to PAI-1.
(B) PAI-1 protein expression was determined
by ELISA from whole cortex homogenates.
Abbreviations are in the legend to Figure 3
(N 5 6 per group). *P , 0.05 vs. VH; #P ,
0.05 vs. CsA.
(P , 0.001). Treatment with L-Arg was successful in CsA nephrotoxicity, but has also been hypothesized to
normalizing the collagen type I mRNA levels to the be important in causing renal dysfunction and ultimately
VH group’s level. No effect relative to collagen type I renal fibrosis [35]. Several studies have suggested that
expression was seen in the six VH-treated groups. On endothelial-derived NO may be involved in the hemody-
the other hand, the mRNA expression of collagen type namic alterations encountered with CsA treatment
IV (shown in Figs. 2 and 7B) was similar in all the treat- [24, 36]. CsA-induced acute renal dysfunction was shown
ment groups, indicating that the effect of CsA on colla- to improve by the simultaneous administration of L-Arg
gen synthesis was specific to collagen type I. in rats [18], while NO blockade with L-NAME enhanced
acute CsA nephrotoxicity [25]. NO modulation was also
DISCUSSION shown to be involved in ameliorating or worsening the
effect of other nephrotoxic drugs, perhaps indicating aThe vasoconstricting effect of CsA on the renal vascu-
lature clearly has been shown to be involved in acute nonspecific effect on the kidney. However, most of the
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and matrix protein expression was not observed in the
VH groups, ruling out a nonspecific effect and suggesting
a specific modulatory effect on CsA. We then proposed
that NO modulation affected fibrosis by altering TGF-b1
expression, which then resulted in increased matrix de-
position and decreased matrix degradation through in-
creased PAI-1.
Our study also showed that urinary NO excretion is
enhanced with L-Arg treatment and blocked by L-NAME.
We are aware of a recent study that suggested that uri-
nary nitrite plus nitrate measurements may not accu-
rately reflect acute NO generation [38]. However, our
results are in agreement with other findings in the rem-
nant kidney model of chronic renal failure [39] and in
rats with unilateral kidney obstruction [37].
In addition to its effect on glomerular hemodynamics,
NO plays a direct role in modulating fibrosis [40]. Indeed,
in vitro and in vivo studies suggest that iNOS-generated
NO may be antifibrotic and therefore may serve to limit
the severity of glomerular and interstitial fibrosis [41].
Rats with unilateral ureteral obstruction treated withFig. 5. Northern blot expression of biglycan mRNA in rat kidneys
L-Arg showed a reduced expression of collagen type IV,relative to GAPDH. Total RNA was isolated from whole cortex at
7 and 28 days and was hybridized with a cDNA probe to biglycan. a-smooth muscle actin, and tissue-inhibitor of metallo-
Abbreviations are in the legend to Figure 3 (N 5 6 per group). *P , proteinase-1 mRNA [37]. In another study, the addition0.05 vs. VH; #P , 0.05 vs. CsA.
of NO-generating compounds to vascular smooth muscle
cells [42] or mesangial cells [16] in culture significantly
decreased collagen synthesis, although the exact mecha-
studies investigating the role of the L-Arg/NO pathway nism of this beneficial effect was not determined. Similar
have looked at the short-term administration of CsA. findings were observed in the remnant kidney model
More recently, L-Arg administration was shown to be in which L-Arg administration reduced proteinuria and
beneficial in experimental chronic CsA nephrotoxicity decreased the number of abnormal glomeruli and the
by limiting tubulointerstitial fibrosis and tubular atrophy severity of the tubulointerstitial changes [11]. In addi-
[26]. However, the exact molecular mechanism underly- tion, diabetic rats given L-Arg had a significantly lower
ing this beneficial effect has not yet been determined. protein excretion; L-Arg also prevented the develop-
The current data confirm that chronic NO blockade ment of hyperfiltration despite persistent hyperglycemia
with L-NAME worsens and chronic NO enhancement [12]. The role of NO in glomerular diseases, however,
with L-Arg attenuates chronic CsA nephrotoxicity. Both remains controversial since it provides protection in
the functional and structural manifestations of chronic some models while it has a detrimental effect in other
CsA nephrotoxicity were affected. We have previously models of glomerulonephritis [10, 40, 41, 43]. In this
shown an elevated expression of TGF-b1, PAI-1, and article, we found significant reductions in the expression
certain matrix components in this model of chronic CsA of various matrix components, including proteoglycans,
nephrotoxicity [5–7]. In the current experiment, inhib- biglycans, and collagens.
iting NO production with L-NAME was associated with It was postulated that some of the beneficial effects
an increased TGF-b1 expression, which in turn was asso- of NO on decreasing fibrosis are related to decreasing
ciated with an increase in the accumulation of matrix the amount of macrophage infiltration, as shown in ob-
components; PAI-1 expression was also increased. On structive nephropathy, in puromycin-induced nephrosis,
the other hand, therapy with L-Arg was associated with and in the remnant kidney model [17, 37, 39, 41]. Simi-
a decrease in TGF-b1, PAI-1, and matrix proteins. These larly, our CsA model displays features of interstitial in-
results are similar to the observation in a model of ob- flammation, including a mononuclear infiltrate. This
structive nephropathy in which NO generation amelio- macrophage influx occurs early and precedes interstitial
rated tubulointerstitial fibrosis, although the expression fibrosis [44]. It was also observed when low CsA doses
of TGF-b1 mRNA was not affected [37]. In our experi- were used in the setting of preserved renal blood flow
ment, this effect seems to be specific since type IV colla- and preceded increases in arteriolar TGF-b expression
gen expression was not influenced by NO modulation. [45]. Although the degree of this mononuclear infiltrate
was not quantitated in this study, we have noted a de-In addition, the impact of NO modulation on TGF-b1
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Fig. 6. Fibronectin protein expression by
ELISA in rat kidneys. PAI-1 protein expres-
sion was determined by ELISA from whole
cortex homogenates. Abbreviations are in the
legend to Figure 3 (N 5 6 per group). *P ,
0.05 vs. VH; #P , 0.05 vs. CsA.
crease in the amount of this infiltrate with L-Arg treat- II receptor blocker [7]. Ang II and TGF-b are known
ment (unpublished observation), suggesting that it may to inhibit cytokine-induced NO production in vascular
also be a contributory factor. In addition to the pre- smooth muscle cells, macrophages, astroglial cells, and
viously mentioned, one can speculate that the NO pro- recently, mesangial cells [56–59]. Ang II was shown to
tective effect may also be related to its ability to inhibit decrease NO production in these cell lines by inhibiting
leukocyte recruitment through a P-selectin mechanism NOS-II gene expression. TGF-b was shown to decrease
[46], to inhibit adhesion molecules [47], and to inhibit NO production in macrophages by decreasing the stabil-
the aggregation of platelets [48], a major source of TGF-b ity and translation of NOS-II mRNA and by increasing
production. the degradation of NOS-II protein [57]. In mesangial
There are many reports that implicate angiotensin II cells, TGF-b markedly decreases the half-life and steady-
(Ang II) as a trigger for NO production. Studies using state levels of NOS-II mRNA [59]. No matter what the
afferent arteriolar vessel preparations show that NOS mechanism of action, inhibition of NO production might
blockade is associated with increased response to Ang be one of the mechanisms by which Ang II and TGF-b
II, as indexed by larger and prolonged reduction of arte- accelerate fibrosis in renal diseases. This, in turn, may
riolar lumen in vitro [49]. On the other hand, Ang II partly explain the beneficial effect on fibrosis with Ang
receptor blockers or angiotensin-converting enzyme II blockade or with NO supplementation in chronic CsA
(ACE) inhibitors prevent most of the changes in the nephrotoxicity. However, similar to Ang II blockade [7],
renal and glomerular hemodynamics induced by NOS NO supplementation in this experiment did not totally
blockade [50, 51]. More specifically, the CsA-mediated prevent fibrosis, suggesting that a number of mechanisms
inhibition of NO synthesis resulted in the activation of may be involved in the development of chronic CsA
intrarenal Ang II and abolished glycine-mediated vaso-
nephrotoxicity. In addition, work with chronic models
dilation; however, pretreatment with an Ang II antago-
of fibrosis suggests that, after a point, further tissue injurynist normalized the NO blockade effects [52]. It is also
may not be required to sustain TGF-b overexpression,recognized that ACE inhibitors increase NO generation
indicating that there are components of the fibrotic pro-within the endothelium of tissues [53]. In addition, ACE
cess that can become self-perpetuating.inhibitors increase kinin levels, which indirectly increase
In addition, recent in vitro studies of glomerular mes-endothelial NO formation [54]. These evidence suggest
angial cells exposed to interleukin-1 revealed that cellsthat NO plays a role in antagonizing Ang-II induced
expressing iNOS did not undergo apoptosis, whereasvasoconstriction in the kidney.
cells not expressing iNOS died [60]. While apoptosis isAngiotensin II plays an important role in the progres-
beneficial in some disease processes, it can be deleterioussion of glomerular and tubulointerstitial diseases. It stim-
at times; apoptosis may result in tissue disruption ifulates extracellular matrix protein synthesis, thereby op-
enough cells are lost [61]. In this model, we have pre-posing the effect of NO. Ang II exhibits these actions
viously shown that CsA favors apoptosis as evidencedat least partly through an induction of TGF-b [55]. We
by an up-regulated expression of p53, Bax, and Fas ligandhave previously shown that the RAS is up-regulated in
and a decreased expression of Bcl-2. In addition, theexperimental chronic CsA nephrotoxicity [5, 6], and that
caspase system is activated [62]. If apoptosis is favoredthe expression of TGF-b1 and extracellular matrix pro-
tein synthesis was blunted by an ACE inhibitor or an Ang by NO inhibition, then a state of NO deficiency induced
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fibrosis by altering TGF-b1 expression, which, in turn,
was associated with increased matrix deposition and de-
creased matrix degradation through its effect on PAI-1.
Since TGF-b is implicated in CsA-induced immunosup-
pression, it is still unclear how NO modulation, by affect-
ing TGF-b expression, would impact the immunosuppres-
sive activities of CsA. Whether L-Arg supplementation
will be beneficial in humans treated with CsA remains
unclear. The few human studies evaluating L-Arg sup-
plementation in CsA therapy have not been encouraging.
In one study, CsA-treated liver and renal transplant pa-
tients showed no improvement in renal function with
short-term intravenous infusion of L-Arg [63]. In addi-
tion, L-Arg infusion in renal allograft recipients receiving
CsA did not result in improvement in GFR or renal
vascular resistance [64]. However, those studies looked
at the effect of the short-term administration of L-Arg.
It remains unknown as to whether long-term L-Arg sup-
plementation will be beneficial in preventing or reducing
the renal fibrosis observed with chronic CsA therapy.
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